Research

$\alpha 2^*$ Nicotinic acetylcholine receptors influence hippocampus-dependent learning and memory in adolescent mice

Shahrdad Lotfipour,^{1,6} Celina Mojica,¹ Sakura Nakauchi,² Marcela Lipovsek,³ Sarah Silverstein,¹ Jesse Cushman,⁴ James Tirtorahardjo,⁶ Andrew Poulos,^{4,5} Ana Belén Elgoyhen,³ Katumi Sumikawa,² Michael S. Fanselow,^{1,4} and Jim Boulter¹

¹Department of Psychiatry, University of California, Los Angeles, Los Angeles, California 90095, USA; ²Department of Neurobiology and Behavior, University of California, Irvine, Irvine, California 92612, USA; ³Instituto de Investigaciones en Ingeniería Genética y Biología Molecular, Dr. Héctor N Torres, CONICET, Buenos Aires, C1428ADN, Argentina; ⁴Department of Psychology, University of California, Los Angeles, Los Angeles, California 90095, USA

The absence of $\alpha 2^*$ nicotinic acetylcholine receptors (nAChRs) in oriens lacunosum moleculare (OLM) GABAergic interneurons ablate the facilitation of nicotine-induced hippocampal CA1 long-term potentiation and impair memory. The current study delineated whether genetic mutations of $\alpha 2^*$ nAChRs (*Chrna2*^{L9'S/L9'S} and *Chrna2*^{KO}) influence hippocampus-dependent learning and memory and CA1 synaptic plasticity. We substituted a serine for a leucine (L9'S) in the $\alpha 2$ subunit (encoded by the *Chrna2* gene) to make a hypersensitive nAChR. Using a dorsal hippocampus-dependent task of preexposure-dependent contextual fear conditioning, adolescent hypersensitive *Chrna2*^{L9'S/L9'S} male mice exhibited impaired learning and memory. The deficit was rescued by low-dose nicotine exposure. Electrophysiological studies demonstrated that hypersensitive $\alpha 2$ nAChRs potentiate acetylcholine-induced ion channel flux in oocytes and acute nicotine-induced facilitation of dorsal/intermediate CA1 hippocampal long-term potentiation in *Chrna2*^{L9'S/L9'S} mice. Adolescent male mice null for the $\alpha 2$ nAChR subunit exhibited a baseline deficit in learning that was not reversed by an acute dose of nicotine. These effects were not influenced by locomotor, sensory or anxiety-related measures. Our results demonstrated that $\alpha 2^*$ nAChRs influenced hippocampus-dependent learning and memory, as well as nicotine-facilitated CA1 hippocampal synaptic plasticity.

Acetylcholine and nicotine activate nicotinic acetylcholine receptors (nAChRs) to influence learning and memory, via the release of neurotransmitters and neurotrophic factors. The specific contributions of selective nAChR subunits influencing learning and memory, particularly during development, are poorly understood. Genetic deletion of $\alpha 2^*$ nAChRs leads to subtle, yet discernible, potentiation of the first 2 d of nicotine self-administration, context specific withdrawal, emotional memory processing (Lotfipour et al. 2013), and baseline deficits in hippocampus-dependent memory (Kleeman et al. 2016). Developmental dysregulation of neural circuits in the absence of $\alpha 2^*$ nAChRs may be responsible for these modifications. $\alpha 2$ (and $\beta 2$) mRNA are expressed within midbrain (interpeduncular nucleus) and limbic brain regions (hippocampus, amygdala, and neocortex) (Deneris et al. 1988; Wada et al. 1988, 1989; Ishii et al. 2005; Upton and Lotfipour 2015; Hilscher et al. 2017). During early postnatal rodent development, particularly during the first 2 wk of life, heightened expression patterns of $\alpha 2^*$ nAChRs are observed within the hippocampus and cortex (Son and Winzer-Serhan 2006). Due to the expression pattern of $\alpha 2^*$ nAChRs, studies have focused

on dissecting the functional roles of these subunits within these brain regions (Nakauchi et al. 2007; Salas et al. 2009).

Within the dorsal through ventral CA1 of the hippocampus, $\alpha 2^*$ nAChRs are located on oriens lacunosum moleculare (OLM) GABAergic interneurons (Sudweeks and Yakel 2000; Son and Winzer-Serhan 2006; Nakauchi et al. 2007, 2015; Leao et al. 2012; Chen et al. 2016; Kleeman et al. 2016). Studies suggest that $\alpha 2^*$ nAChRs play an important role in CA1 hippocampal OLM GABAergic interneurons (Ishii et al. 2005; Nakauchi et al. 2007, 2015; Chen et al. 2016; Kleeman et al. 2016). Deletion of *Chrna2* induces an absence of nicotine facilitation and suppression of hippocampal long-term potentiation (LTP) (Nakauchi et al. 2007), likely via a dysregulation of OLM GABA neurotransmitter release (Leao et al. 2012). Furthermore, early developmental chronic nicotine exposure during peak mRNA expression periods of $\alpha 2^*$ nAChRs (i.e., the first 2 wk of rodent life) is known to influence hippocampal synaptic plasticity and learning and memory during adolescence, likely via $\alpha 2^*$ nAChRs (Nakauchi et al. 2015; Chen et al. 2016; Kleeman et al. 2016). Our current study assessed whether deletion or functional enhancement of $\alpha 2^*$ nAChRs are important for baseline and acute nicotine's effects

⁵Present address: Department of Psychology, Center for Neuroscience, University at Albany, State University of New York, Albany, NY 12222, USA.

⁶Present address: Departments of Emergency Medicine and Pharmacology, University of California, Irvine, Irvine, CA 92697, USA. Corresponding author: shahrdad@uci.edu

Article is online at <http://www.learnmem.org/cgi/doi/10.1101/lm.045369>. 117.

© 2017 Lotfipour et al. This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first 12 months after the full-issue publication date (see <http://learnmem.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

on learning and memory processing. We evaluated this using a dorsal CA1 hippocampus-dependent task of preexposure-dependent contextual fear conditioning in adolescent male mice (Fanselow 1990; Rudy et al. 2002; Cushman et al. 2011). Our findings provide evidence for a role of $\alpha 2^*$ nAChRs in hippocampus-dependent learning and memory and nicotine-facilitated synaptic plasticity in mice.

Results

Adolescent *Chrna2*^{L9'S/L9'S} generation, and developmental stereotypical behavioral characteristics

We genetically engineered the *Chrna2*^{L9'S/WT} mice in our laboratory (Fig. 1). Subsequently, *Chrna2*^{L9'S/WT} mice were backcrossed with C57Bl/6J mice for 3–4 generations. Heterozygous *Chrna2*^{L9'S/WT} $\times$ *Chrna2*^{L9'S/WT} mice were mated for experiments and offspring had expected Mendelian genotype (1:2:1) and sex ratios (50% M, F). The adolescent male *Chrna2*^{L9'S/L9'S} mice exhibited good health, no gross anatomical morphological changes, no differences in stereotypical behaviors (Table 1^{a1}; Fig. 2), and no differences in weight gain compared with wild-type littermate control mice (data not shown).

Oocyte expression

The use of oocyte expression studies (Fig. 3A) was applied as an initial screen to determine the functionality of a substitution of a serine for a leucine (L9'S) in the $\alpha 2$ nAChR subunit. In the presence of acetylcholine (ACh), fitted Hill equations for $\alpha 2\beta 2$ wild-type nicotinic receptors had an EC₅₀ of 3.7 ± 1.0 μ M, which is similar to that previously reported for $\alpha 4\beta 2$ nAChRs, 5.07 ± 2.4 μ M (Lipovsek et al. 2008). $\alpha 2^{L9'}$ mutations produced an increase in the apparent affinity for ACh when expressed in *Xenopus* oocytes together with the $\beta 2$ subunit (Fig. 3A). Thus, the $\alpha 2^{L9'S}$ mutation produced a 100-fold (EC₅₀: 0.041 ± 0.015), the $\alpha 2^{L9'A}$ a 10-fold (EC₅₀: 0.37 ± 0.03) and the $\alpha 2^{L9'T}$ a fivefold decrease in the ACh EC₅₀ (EC₅₀: 0.91 ± 0.04) when compared with $\alpha 2^{WT}$ -containing receptors (EC₅₀: 3.7 ± 1.0) ($n = 3$ per group). Our results confirmed earlier findings in oocytes that had a serine for a leucine (L9'S) substitution in a nAChR subunit induces a 100-fold leftward shift in the acetylcholine EC₅₀ dose response curves (for review, please see Lester et al. 2003). Based on these data, $\alpha 2^{L9'S}$ mutations were chosen for the design and development of the hypersensitive *Chrna2*^{L9'S/L9'S} mouse line (Fig. 1A), because they produced the greatest increase in ACh apparent affinity (Fig. 3A).

Dorsal/intermediate CA1 hippocampal nicotinic facilitation of LTP

We measured the impact of $\alpha 2^{L9'S}$ nAChR expression on synaptic transmission at

the Schaffer collateral (SC) pathway by monitoring stimulus–response relationships. We found no significant differences between slices from control and *Chrna2*^{L9'S/L9'S} mice in the stimulus–response relationships (Fig. 3B), suggesting that the expression of $\alpha 2^{L9'S}$ nAChRs had no significant effect on basal synaptic transmission at the SC pathway. We then monitored LTP induction at the SC pathway using weak theta burst stimulation (TBS) protocol. Previous studies demonstrated that endogenous ACh-mediated activation of $\alpha 2^*$ nAChR-containing OLM cells did not occur during weak TBS at the SC pathway, but bath application of nicotine activated $\alpha 2^*$ -nAChR-containing OLM cells to induce LTP (Nakauchi et al. 2007). Indeed, in both wild-type and *Chrna2*^{L9'S/L9'S} mice, LTP was not induced in the absence of nicotine (Fig. 3C,F; wild-type, $102.0 \pm 2.8\%$, $N = 6$ and *Chrna2*^{L9'S/L9'S}, $100.7 \pm 5.7\%$, $N = 6$ ^{b1}). In wild-type mice, 1 μ M nicotine was required for LTP induction (Nakauchi et al. 2007), whereas we found that in *Chrna2*^{L9'S/L9'S} mice, 0.1 μ M nicotine (Fig. 3E,F; wild type, $107.3 \pm 3.4\%$, $n = 9$ versus *Chrna2*^{L9'S/L9'S}, $159.3 \pm 21.4\%$, $N = 6$, $P = 0.033$, Bonferroni-corrected^{b2}) or 0.01 μ M nicotine (Fig. 3D,F; wild type, $99.4 \pm 7.8\%$, $N = 7$ versus *Chrna2*^{L9'S/L9'S}, $133.7 \pm 9.3\%$, $N = 8$, $P = 0.045$, Bonferroni-corrected^{b3}) was sufficient for LTP induction. These findings suggest that $\alpha 2^{L9'S}$ nAChRs were activated by lower concentrations of nicotine to induce LTP. Overall, the findings indicate that $\alpha 2^*$ nAChRs are capable of participating in nicotinic facilitation of LTP at the SC pathway.

Figure 1. Genetic design of the hypersensitive *Chrna2*^{L9'S/L9'S} mouse line. (A) The generation of the hypersensitive *Chrna2*^{L9'S/L9'S} mouse line has been described in the Materials and Methods. Briefly, a leucine to serine substitution was engineered using gene synthesis. The targeting vector was electroporated into 129S4/SvJae embryonic stem (ES) cells and homologous recombinants were confirmed through DNA sequencing (B) and Southern blot analysis (using the probe denoted by the single red line) (C). Targeted ES cells were microinjected into C57Bl/6J blastocyst embryos and implanted in pseudopregnant female mice, with the DNA sequence of the germline transmitted offspring confirming the AGC (Serine)/CTC (Leucine) heterozygous genomic modification (denoted by *). Genotyping of mice of was through tail biopsy, MyTaq HS Red Mix (Bioline) with PCR primers (A2L9S_1.10, A2L9S_1.11, denoted by arrows flanking the 34 bp FRT Site) designed upstream of and downstream from the deleted PGK-NEO, as described (FRT site denoted by the single arrow).

Table 1. Statistics table

Symbol	Result	Data structure	Type of test	P-value, power, and LSN	N
a1	Figure 2, Stereotypic behaviors	Normal distribution	Two-way ANOVA	n.s. for genotype, drug or Genotype $\times$ Drug	N = 12–16
b1-3	Figure 3F, Electrophysiology data, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal Distribution	T-test (a1–3)	(b1) <i>P</i> = n.s., (saline), (b2) (*) <i>P</i> = 0.033, Bonferroni-corrected, power: 0.8 (0.1 μ M nicotine), (b3)(*) <i>P</i> = 0.045, Bonferroni-corrected, power: 0.7, (0.01 μ M nicotine)	N = 6–9
c	Figure 4B D1 versus D3, Learning and memory data, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	Matched pairs t-test	(**) <i>P</i> = 0.002, Bonferroni-corrected, power: 1.0 for nicotine-treated <i>Chrna2</i> ^{L9/S/L9/S} Mice, (***) <i>P</i> = 0.001, Bonferroni-corrected, power: 1.0 for saline-treated wild-type mice, (****) <i>P</i> = 0.0004, Bonferroni-corrected, power: 1.0 for nicotine-treated wild-type mice, LSN: 16 for saline-treated <i>Chrna2</i> ^{L9/S/L9/S} mice (current N = 12)	N = 12–16
d1-3	Figure 4C D2, Learning and memory data, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	Two-way ANOVA	(d1–3) <i>P</i> = n.s. n.s. for Genotype, Drug, or Genotype $\times$ Drug	N = 12–16
e1-2	Figure 4B D3, Learning and memory data, <i>Chrna2</i> ^{L9/S/L9/S} Mice	Normal distribution	Two-way ANOVA (e1), least square means differences Student's <i>t</i> -test (e2)	(e1) <i>P</i> = 0.02, Power: 0.7 for the interaction of Genotype $\times$ Drug, (e2) (*) <i>P</i> = 0.03, Bonferroni-corrected, power: 0.8 for wild-type saline-treated mice versus saline-treated <i>Chrna2</i> ^{L9/S/L9/S} mice for day 3	N = 12–16
f1-2	Figure 5A, Rearing, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	Two-way ANOVA, least-square means differences Student's <i>t</i> -test	(f1) <i>P</i> = 0.02, Power = 0.7 for the main effect of genotype, (f2) <i>P</i> = 0.03, power = 0.6 for the Interaction of genotype $\times$ drug, Bonferroni-corrected, <i>P</i> = 0.02, power: 0.9 for saline-treated <i>Chrna2</i> ^{L9/S/L9/S} mice versus saline-treated wild-type mice, Bonferroni-corrected, <i>P</i> = 0.049, power: 0.8 for saline-treated <i>Chrna2</i> ^{L9/S/L9/S} mice versus nicotine-treated wild-type mice, Bonferroni-corrected, <i>P</i> = 0.06 for saline-treated <i>Chrna2</i> ^{L9/S/L9/S} mice versus nicotine-treated <i>Chrna2</i> ^{L9/S/L9/S} mice	N = 28(f1) N = 12–16 (f2)
g1-2	Figure 5B, Mid-line crosses, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	Two-way ANOVA	(g1)(*) <i>P</i> = 0.002, power = 0.9 for main effect of genotype, (g2) <i>P</i> = n.s. for Genotype $\times$ Drug interaction	N = 28
h	Figure 5C,D, Anxiety: center/perimeter time, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution*	Two-way ANOVA	<i>P</i> = n.s. n.s. for Genotype, Drug, or Genotype $\times$ Drug	N = 12–16
i	Figure 5E, Locomotor activity, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	ANOVA	(**) <i>P</i> = 0.004, power = 0.9 for the main effect of genotype	N = 28
j	Figure 5F, Shock reactivity, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	Two-way ANOVA	(*) <i>P</i> = 0.02, power = 0.7 for the main effect of genotype	N = 28
k	Figure 6, Stereotypic behaviors	Normal distribution	Two-way ANOVA	n.s. for Genotype, Drug or Genotype $\times$ Drug	N = 5–8
l1-3	Figure 7B D2, Learning and memory data, <i>Chrna2</i> ^{KO} mice	Normal distribution	Two-way ANOVA, least square means differences Student's <i>t</i> -test	(l1) <i>P</i> = 0.03, power: 0.6 for main effect of genotype, (l2) <i>P</i> = 0.02, power: 0.7 for Genotype $\times$ Drug Interaction, (*) <i>P</i> = 0.02, (l3) Bonferroni-corrected, power: 0.9 for nicotine-treated wild-type mice versus nicotine-treated <i>Chrna2</i> ^{KO} mice	N = 11–14(l1–2) N = 5–8(l3)
m	Figure 7 D3, Learning and memory data, <i>Chrna2</i> ^{KO} Mice	Normal distribution	Two-way ANOVA	(*) <i>P</i> = 0.02, Power: 0.7 for main effect of genotype	N = 11–14
n	Figure 8A, Rearing, <i>Chrna2</i> ^{KO} mice	Normal Distribution	Two-way ANOVA, Least Square means differences Student's <i>t</i> -test	<i>P</i> = 0.052, LSN: 49 for Genotype $\times$ Drug interaction (current N = 25 for total sample of N = 5–8 per group)	N = 5–8
o1-4	Figure 8B, Mid-line crosses, <i>Chrna2</i> ^{KO} mice	Normal distribution	Two-way ANOVA, least square means differences Student's <i>t</i> -test	(o1) = 0.01 for main effect of genotype, (o2) = 0.04 for main effect of drug, (o3) = 0.04 for Genotype $\times$ Drug interaction, power = 0.6, (o4) <i>P</i> = 0.02, Bonferroni-corrected, power: 0.9 for nicotine-treated <i>Chrna2</i> ^{KO} mice versus all other groups: nicotine-treated wild-type mice, saline-treated wild-type mice, and saline-treated <i>Chrna2</i> ^{KO} mice	N = 5–8
p	Figure 8C,D, Anxiety: center/perimeter time, <i>Chrna2</i> ^{L9/S/L9/S} mice	Normal distribution	Two-way ANOVA	<i>P</i> = n.s. n.s. for Genotype, Drug, or Genotype $\times$ Drug	N = 5–8

Continued

Table 1. Continued

Symbol	Result	Data structure	Type of test	P-value, power, and LSN	N
q	Figure 8E, Locomotor data, <i>Chrna2</i> ^{KO} mice	Normal distribution	Two-way ANOVA	(**) $P = 0.01$, power = 0.8 for main effect of genotype	$N = 28$
r	Figure 8F, Shock reactivity, <i>Chrna2</i> ^{KO} mice	Normal distribution	Two-way ANOVA, least square means Student's <i>t</i> -test	$P = 0.01$, Power = 0.8 for Genotype $\times$ Drug interaction, Bonferroni-corrected post hoc comparison were not significant	$N = 5-8$

LSN: Least significant number (i.e., total “*n*”) needed to attain significance at an $\alpha = 0.05$ and a power of 0.8 (see LSN definition in JMP, 12.0.1). Power values less than 0.8 are considered underpowered, if a significant difference is present (see parameter power definition in JMP, 12.0.1). While an interaction could provide a low power (e.g., e1), the post hoc test can illustrate sufficient power (e.g., e2). Please note that there are more cases that are underpowered in data collected from the *Chrna2*^{KO} mice versus the *Chrna2*^{L9S/L9S} mice. This is mainly due to the reduced “*n*” in the *Chrna2*^{KO} mouse population (i.e., $N = 5-8$ per group for *Chrna2*^{KO} mice versus $N = 12-16$ per group for *Chrna2*^{L9S/L9S} mice). For transparency, we have retained the data and power analyses in our study. We have not included LSN's that require a high “*n*” to lead to significance. *For anxiety behavior in *Chrna2*^{L9S/L9S} mice, a normal distribution was found in two of four groups.

Preexposure-dependent contextual fear conditioning in adolescent mice

We assessed nicotine modulated hippocampus-dependent learning and memory in our *Chrna2*^{L9S/L9S} mouse line compared with their wild-type littermate controls (heterozygous mice were not assessed in these studies) (Fig. 4A–C). The learning and memory task we used was a preexposure-dependent contextual fear conditioning procedure, which is dorsal hippocampus-dependent (Fanselow 1990; Wiltgen et al. 2001; Rudy et al. 2002; Kenney and Gould 2008; Cushman et al. 2011). In the current studies, we hypothesized that *Chrna2*^{L9S/L9S} mice would exhibit modifications in nicotine-facilitated learning and memory. As a measure of conditioning, we examined changes in individual animals freezing from day 1 (preexposure) to day 3 (context test) using matched-pair *t*-tests (Bonferroni-corrected for multiple comparisons holding $\alpha = 0.05^b$) ((**) $P = 0.002$, Bonferroni-corrected; (***) $P = 0.001$, Bonferroni-corrected, (****) $P = 0.0004$, Bonferroni-corrected, $N = 12-16$ per group) (Fig. 4^c). A significant enhancement of freezing occurred for all genotypes and drug treatments on context test, except for the *Chrna2*^{L9S/L9S} saline-treated mice (Fig. 4B). For day 2, using a two-way ANOVA, we observed no main effects for Genotype ($F_{(1,52)} = 0.07$, $P = \text{n.s.}^{d1}$), Drug (Nicotine versus Saline) ($F_{(1,52)} = 1.68$, $P = \text{n.s.}^{d2}$), or Genotype $\times$ Drug ($F_{(1,52)} = 1.51$, $P = \text{n.s.}^{d3}$) interaction (Fig. 4C). For day 3, a two-

way ANOVA revealed a Genotype $\times$ Drug Treatment (Nicotine versus Saline) interaction ($F_{(1,52)} = 6.12$, $P = 0.02$, $N = 12-16$ per group^{e1}, Fig. 4B). Bonferroni-corrected post hoc analysis demonstrated saline-treated *Chrna2*^{L9S/L9S} mice had significantly reduced freezing behavior when compared with saline-treated wild-type mice ($P = 0.03^{e2}$, Fig. 4B). The reduced freezing behavior in *Chrna2*^{L9S/L9S} mice was absent after nicotine treatment. The findings support the conclusion that saline-treated *Chrna2*^{L9S/L9S} mice failed to exhibit enhanced freezing on day 3 when compared with day 1, likely due to a deficit to acquire and encode appropriate contextual representations during preexposure day 1. We refer to this loss of freezing behavior in saline-treated *Chrna2*^{L9S/L9S} mice as a baseline deficit in hippocampus-dependent learning and memory.

Activity measures in *Chrna2*^{L9S/L9S} mice

We tested whether or not changes in learning and memory (as assessed by freezing behavior) were confounded by modifications in other types of behaviors, including locomotor, sensory, and anxiety behavior (Fig. 5). After an acute treatment to saline or nicotine, we measured automated locomotor activity (a robust measure of locomotor activity, Cushman et al. 2011), rearing, mid-line crosses (exploratory behavior), center and perimeter time (anxiety behavior) as animals were preexposed to the conditioning chamber (i.e., a novel environment) on day 1. We also assessed shock reactivity (sensory response) on day 2 across the 2 sec of the 0.75 mA shock and the 2 sec after.

For rearing (exploratory vertical movement), two-way ANOVA revealed a main effect for Genotype ($F_{(1,52)} = 5.75$, $P = 0.02$, $N = 28$ per group^{f1}) and an interaction for Genotype $\times$ Drug Treatment ($F_{(1,52)} = 4.91$, $P = 0.03$, $N = 12-16$ per group^{f2}). Bonferroni-corrected *t*-test post hoc analysis revealed that saline-treated *Chrna2*^{L9S/L9S} mice had significantly greater rearing behavior than wild-type saline ($P = 0.02$) and nicotine-treated mice ($P = 0.049$), but not nicotine-treated *Chrna2*^{L9S/L9S} mice ($P = 0.06$) (Fig. 5A). For mid-line crossing behavior (exploratory horizontal movement), two-way ANOVA revealed a main effect for Genotype ($F_{(1,52)} = 10.89$, $P = 0.002$, $N = 28$ per group^{g1}) and no interaction for Genotype $\times$ Drug Treatment ($F_{(1,52)} = 3.33$, $P = \text{n.s.}$, $N = 12-16$ per group^{g2}, Fig. 5B). Significant main effect analysis for Genotype revealed that *Chrna2*^{L9S/L9S} mice have increased mid-line crosses when compared with wild-type mice ((*) $P = 0.002$). For anxiety behavior, we quantified center and perimeter time on day 1, within the contextual fear conditioning chamber. An increase in center time was regarded as reduced anxiety. For center (and perimeter) time anxiety measures, a two-way ANOVA demonstrated no main effect for Genotype ($F_{(1,52)} = 2.92$, $P = \text{n.s.}$), Drug (Nicotine versus Saline) ($F_{(1,52)} = 0.18$, $P = \text{n.s.}$), or

Figure 2. Stereotypic behaviors were assessed in wild-type and *Chrna2*^{L9S} mice on day 1. Results illustrated that stereotypic behaviors do not differ based on drug treatment or genotype. $N = 12-16$ per group.

Figure 3. (A) $\alpha 2^{L9^S}$ nicotinic receptor modifications potentiated ACh-induced ion channel conductance by 100-fold (closed circles) versus wild-type $\alpha 2$ -containing nicotinic receptors (open circles) in oocyte expression studies, 10-fold against $\alpha 2^{L9^A}$ (closed squares), fivefold against $\alpha 2^{L9^T}$ (closed diamonds)-containing nAChRs. Based on this data, $\alpha 2^{L9^S}$ mutations were chosen for the design of the hypersensitive *Chrna2*^{L9^S/L9^S} mouse line, because they produced the greatest increase in ACh apparent affinity. (B–F) Lower concentrations of nicotine facilitate LTP induction at CA3–CA1 synapses in *Chrna2*^{L9^S/L9^S} mice. (B) There was no significant difference between slices from wild-type and *Chrna2*^{L9^S/L9^S} mice in the stimulus–response relationship. (C, F) LTP was not induced in the absence of nicotine in both wild-type and *Chrna2*^{L9^S/L9^S} mice. (D–F) Bath application of nicotine (0.01 μ M nicotine in C and 0.1 μ M in D) facilitated LTP induction in *Chrna2*^{L9^S/L9^S}, but not wild-type, mice. Administration of nicotine is indicated by the horizontal bar. Traces above each graph (C–E) are representative waveforms recorded before and 50–60 min after weak TBS. Scale bar: 1 mV, 10 msec. (E) Histograms show the percent change (mean $\pm$ SEM) in the slope of fEPSPs measured 50–60 min after delivery of weak TBS. Numbers in parentheses indicate the numbers of experiments, (*) $P < 0.05$, Bonferroni-corrected.

Genotype $\times$ Drug ($F_{(1,52)} = 1.54$, $P = \text{n.s.}^h$) interaction (Fig. 5C,D). The findings highlighted that anxiety measures were not influenced by genotype or acute drug treatment. Independent of genotype or drug treatment, mice spent significantly greater time on the perimeter versus center of the open field chamber (524.5 sec in perimeter versus 75.5 sec in center, $P = 0.0001$).

For automated locomotor activity, a two-way ANOVA demonstrated a main effect for Genotype ($F_{(1,52)} = 9.37$, $P = 0.004$, $N = 28$ per group¹), but no other main effect or interaction. Significant main effect analysis for Genotype demonstrated *Chrna2*^{L9^S/L9^S} versus wild-type mice had greater automated locomotor activity on day 1, independent of drug treatment (Fig. 5E). Thus, for both automated locomotor activity and mid-line crosses, hyperactivity was observed in *Chrna2*^{L9^S/L9^S} mice (versus wild-type littermate controls), independent of drug treatment. Rearing

behavior only resolved hyperactivity in saline-treated *Chrna2*^{L9^S/L9^S} mice. Hyperactivity may provide additional evidence of impaired hippocampal function in the *Chrna2*^{L9^S/L9^S} mice, as one effect of hippocampal lesions is hyperactivity (Anagnostaras et al. 1999; Godsill et al. 2005). On the other hand, it is possible that the hyperactivity observed on day 1 in *Chrna2*^{L9^S/L9^S} mice confounds learning and memory deficits on day 3. If this was the case, we predicted that there would be a significant correlation between activity on day 1 and freezing behavior on day 3, with greater activity associated with reduced freezing behavior. Given our learning and memory findings, we predicted that the relationships should be dependent on both genotype and drug treatment, since nicotine treatment rescued the baseline deficit selectively in *Chrna2*^{L9^S/L9^S} mice. When we separated by genotype and drug treatment, significant correlations were not observed for any groups: saline-treated *Chrna2*^{WT} mice: $R^2 = 0.004$, $P = \text{n.s.}$; nicotine-treated *Chrna2*^{WT} mice: $R^2 = 0.003$, $P = \text{n.s.}$; saline-treated *Chrna2*^{L9^S/L9^S} mice: $R^2 = 0.07$, $P = \text{n.s.}$; nicotine-treated *Chrna2*^{L9^S/L9^S} mice: $R^2 = 0.09$, $P = \text{n.s.}$, $n = 12$ –16 per group. The results did not illustrate selective correlations in saline or nicotine-treated *Chrna2*^{L9^S/L9^S} mice. Thus, we do not believe that hyperactivity on day 1 confounded interpretations of our learning and memory results on day 3.

For changes in sensory response, we assessed the impacts of shock reactivity for all groups of mice. For shock reactivity, a two-way ANOVA revealed a significant effect for Genotype ($F_{(1,52)} = 5.81$, $P = 0.02$, $N = 28$ per group¹) and no other main effect or interaction. Significant main effect analysis for Genotype demonstrated that *Chrna2*^{L9^S/L9^S} mice have greater shock reactivity versus wild-type control mice, independent of drug exposure (Fig. 5F). Increased shock reactivity may indicate increased pain sensitivity (i.e., sensory response). In *Chrna2*^{L9^S/L9^S} mice, however, this would be expected to produce increased freezing, rather than the decrease that was observed in saline-treated *Chrna2*^{L9^S/L9^S} mice, arguing that altered sensory response cannot explain the results. Thus, our results suggest that our learning and memory observations are not confounded by modifications in other types of behaviors, including locomotor, sensory, or anxiety behaviors.

Adolescent *Chrna2*^{KO} stereotypical behavioral characteristics

We have previously described the genetic design, absence of gross anatomical morphological changes and behavioral characterization of adult *Chrna2*^{KO} mice (Lotfipour et al. 2013).

Figure 4. *Chrna2^{L9S/L9S}* mice exhibit deficits in a hippocampus-dependent learning and memory preexposure contextual fear conditioning behavioral task. (A) On day 1 (preexposure, PE), adolescent mice were administered saline or nicotine (0.09 mg/kg/inj, i.p.) 3–5 min prior to being preexposed to a novel environment for 8 min where freezing and automated locomotor activity was recorded. On day 2 (Immediate-Shock, IS), mice received a 2-sec 0.75-mA shock and shock reactivity was assessed. On day 3, (Context Test, CT) animals were administered a second vehicle or nicotine injection 3–5 min prior to being tested for freezing behavior for 8 min. (B) As a measure of conditioning, we examined changes in individual animals freezing from day 1 (preexposure) to day 3 (context test) using matched-pair *t*-tests (Bonferroni-corrected for multiple comparisons holding $\alpha = 0.05^*$). Bonferroni-corrected post hoc comparisons illustrate that (i) saline-treated adolescent *Chrna2^{L9S/L9S}* mice exhibited deficits in the enhancement freezing behavior post-shock, and (ii) nicotine treatment enhanced freezing behavior on context day in adolescent *Chrna2^{L9S/L9S}* mice. (** $P = 0.002$ Bonferroni-corrected; (***) $P = 0.001$, Bonferroni-corrected, (****) $P = 0.0004$, Bonferroni-corrected, $N = 12$ –16 per group. For day 3 (CT), post hoc analysis demonstrates saline-treated wild-type mice have significantly greater freezing behavior than *Chrna2^{L9S/L9S}* saline-treated mice. $N = 12$ –16 per group (*) $P = 0.03$, Bonferroni-corrected. (C) No significant effects were observed for genotype or drug treatment on day 2 (IS) in adolescent *Chrna2^{L9S/L9S}* mice.

Adolescent *Chrna2^{KO}* mice had no differences in weight gain or stereotypical behaviors observed in a novel environment compared with wild-type littermate control mice (Fig. 6^b). Thus, no growth or development modifications were observed in adolescent *Chrna2^{KO}* mice.

Preexposure-dependent contextual fear conditioning in adolescent *Chrna2^{KO}* mice

Using *Chrna2^{KO}* mice, which exhibit an absence of nicotine-induced facilitation and depression of LTP during adolescence (Nakauchi et al. 2007), we predicted that we would observe an absence of nicotine-facilitated learning and memory in these mutant mice (Fig. 7). As a measure of conditioning, we examined changes in individual animals freezing from day 1 (preexposure) to day 3 (context test) using Bonferroni-corrected matched-pair *t*-tests. Data demonstrated a significant enhancement of freezing behavior in all groups (*) $P = 0.048$, Bonferroni-corrected, (**) $P = 0.01$, Bonferroni-corrected, (***) $P = 0.004$, Bonferroni-corrected, $N = 5$ –8 per group, Fig. 7A). For day 2, using a two-way ANOVA, a main effect was observed for Genotype ($F_{(1,21)} = 5.20$, $P = 0.03^{11}$) as well as a Genotype $\times$ Drug Treatment (Nicotine versus Saline) interaction ($F_{(1,21)} = 6.88$, $P = 0.02$, $N = 5$ –8 per group¹²). Bonferroni-corrected *t*-test post hoc analysis revealed that wild-type nicotine-treated mice had significantly greater freezing behavior than nicotine-treated *Chrna2^{KO}* mice ($P = 0.02^{13}$, Fig. 7B). The findings suggest that nicotine-treated

adolescent *Chrna2^{KO}* mice had a deficit in learning and memory on day 2, when compared with nicotine-treated *Chrna2^{WT}* mice. For day 3, a two-way ANOVA revealed a main effect for Genotype ($F_{(1,21)} = 6.56$, $P = 0.02^m$) but no Genotype $\times$ Drug Treatment (Nicotine versus Saline) interaction. Significant main effect analysis for Genotype revealed that wild-type mice had greater freezing behavior than *Chrna2^{KO}* mice, independent of drug treatment (Fig. 7). Overall, the findings highlighted that *Chrna2^{KO}* mice exhibited deficits in contextual learning during the preexposure that were not rescued by acute nicotine exposure.

Activity measures in *Chrna2^{KO}* mice

We tested whether or not changes in learning and memory (as assessed by freezing behavior) were confounded by modifications in other types of behaviors, including locomotor, sensory, or anxiety-related behaviors (Fig. 8). After an acute treatment to saline or nicotine, we measured rearing, mid-line crosses, center time, and automated locomotor activity as animals were preexposed to the conditioning apparatus on day 1. We also assessed shock reactivity on day 2 (Fig. 8F). For rearing (exploratory vertical movement) behavior, two-way ANOVA failed to reach a significant main effect or interaction for Genotype $\times$ Drug Treatment ($F_{(1,21)} = 4.23$, $P = 0.052$, $N = 5$ –8 per groupⁿ, Fig. 8A). For mid-line crossing behavior (exploratory horizontal movement), two-way ANOVA revealed a main effect for Genotype ($F_{(1,21)} = 7.34$, $P = 0.01^{o1}$), a main effect for Drug Treatment ($F_{(1,21)} = 4.55$, $P = 0.04^{o2}$) and an interactive effect for Genotype $\times$ Drug Treatment ($F_{(1,21)} = 4.97$, $P = 0.04$, $N = 5$ –8 per group^{o3}, Fig. 8B). Bonferroni-corrected *t*-test post hoc analysis revealed nicotine-treated *Chrna2^{KO}* had significantly greater mid-line crosses than all other groups ($P = 0.02^{o4}$). For anxiety behavior, we assessed center (Fig. 8C) and perimeter time (Fig. 8D) within the contextual fear conditioning chamber. For anxiety measures, a two-way ANOVA demonstrated no main effect for Genotype ($F_{(1,21)} = 0.35$, $P = \text{n.s.}$), Drug (Nicotine versus Saline) ($F_{(1,21)} = 0.97$, $P = \text{n.s.}$), or Genotype $\times$ Drug ($F_{(1,52)} = 0.74$, $P = \text{n.s.}$) interaction (Fig. 8C,D). The findings highlighted that anxiety, as measured by an increase in center time, was not influenced by genotype or acute drug treatment. Independent of genotype or drug treatment, mice spent significantly greater time on the perimeter versus center of the open field chamber (522.1 sec in perimeter versus 77.9 sec in center, $P = 0.0001$).

For automated locomotor activity, two-way ANOVA demonstrated a main effect for Genotype ($F_{(1,21)} = 9.09$, $P = 0.01^q$), but no other main effect or interaction. Greater activity was observed on day 1 in *Chrna2^{KO}* versus wild-type mice, independent of drug treatment (Fig. 8E). To determine whether hyperactivity confounded our learning and memory results, we assessed simple linear correlations between activity on day 1 and freezing behavior on day 3 of context test. When we separated by genotype and drug treatment, significant correlations were not observed for

Figure 5. Locomotor (rearing/vertical, mid-line crosses/vertical, automated vertical/horizontal), anxiety (center/perimeter time) and sensory response (shock reactivity) were assessed in wild-type littermate control and *Chrna2*^{L9S/L9S} mice. Behaviors were assessed in the contextual fear conditioning chamber during the preexposure period on day 1 (PE, Fig. 5A). Shock reactivity was assessed on day 2 (IS, Fig. 5A) using the Med Associated Automated video tracking system. (A) For rearing behavior, Bonferroni-corrected post hoc comparisons illustrate saline-treated *Chrna2*^{L9S/L9S} mice exhibited enhanced vertical movements versus saline and nicotine-treated wild-type mice littermate control mice. $N = 12-16$ per group, (***) $P = 0.02$, (*) $P = 0.049$. (B) For mid-line crosses, *Chrna2*^{L9S/L9S} mice exhibited enhanced activity, independent of drug treatment. $N = 28$ per group, (***) $P = 0.002$ for mid-line crosses. (C,D) For anxiety, center or perimeter time did not differ in *Chrna2*^{L9S/L9S} of wild-type littermate control mice, independent of drug treatment. $N = 12-16$ per group. (E) For automated locomotor activity, *Chrna2*^{L9S/L9S} mice exhibited enhanced activity, independent of drug treatment. $N = 28$ per group, (***) $P = 0.004$ for automated locomotion. (F) For sensory response (shock reactivity), *Chrna2*^{L9S/L9S} versus wild-type littermate control mice exhibited enhanced shock reactivity on day 2, independent of drug treatment on preexposure day 1. $N = 28$ per group, (*) $P = 0.02$.

any groups: saline-treated *Chrna2*^{WT} mice: $R^2 = 0.11$, $P = \text{n.s.}$; nicotine-treated *Chrna2*^{WT} mice: $R^2 = 0.36$, $P = \text{n.s.}$; saline-treated *Chrna2*^{KO} mice: $R^2 = 0.02$, $P = \text{n.s.}$; nicotine-treated *Chrna2*^{KO} mice: $R^2 = 0.002$, $P = \text{n.s.}$, $n = 5-8$ per group. Additionally, when we collapsed by drug treatment, again we observed no significant correlation between activity on day 1 and freezing behavior on day 3 of context test: *Chrna2*^{WT} mice: $R^2 = 0.12$, $P = \text{n.s.}$; *Chrna2*^{KO} mice: $R^2 = 0.02$, $P = \text{n.s.}$; $n = 11-14$. The results did not illustrate selective correlations in *Chrna2*^{KO} mice. Thus, we do not believe that hyperactivity on day 1 confounded interpretations of our learning and memory results on day 3.

For shock reactivity across the 2 sec of the 0.75-mA shock and the 2 sec after, two-way ANOVA revealed a significant interaction for Genotype $\times$ Drug Treatment ($F_{(1,21)} = 9.05$, $P = 0.01$, $N = 5-8$ per group¹) with no main effects observed. Bonferroni-corrected t -test post hoc analysis failed to reach statistical significance for any of the comparisons (Fig. 8F). The findings provide convergent evidence for impaired hippocampal function, similar to the pattern seen in *Chrna2*^{L9S/L9S} mice. The findings strongly suggest that our learning and memory observations are not confounded by modifications in other types of behaviors.

Discussion

The current study tested the hypothesis that genetic mutations of $\alpha 2^*$ nAChRs in *Chrna2*^{L9S/L9S}, but not *Chrna2*^{KO} mice, would pro-

duce modifications in nicotine-induced hippocampus-dependent learning and memory. When we substituted a serine for a leucine (L9S) in the $\alpha 2$ subunit (encoded by the *Chrna2* gene) to make a hypersensitive nAChR, we confirmed the mutation potentiates acetylcholine-induced ion channel flux in oocytes. Subsequently, in adolescent *Chrna2*^{L9S/L9S} mice, we observed a potentiation of nicotine-induced facilitation of synaptic plasticity in hippocampal electrophysiological studies at subthreshold doses of nicotine (0.01 and 0.1 μM). Using a preexposure-dependent contextual fear paradigm (Wiltgen et al. 2001; Rudy et al. 2002; Stote and Fanselow 2004; Cushman et al. 2011), we observed an impairment in freezing behavior (i.e., baseline deficit) in both adolescent *Chrna2*^{L9S/L9S} and *Chrna2*^{KO} mice. A subthreshold dose of nicotine (0.09 mg/kg per injection), was able to rescue the baseline deficit in *Chrna2*^{L9S/L9S}, but not *Chrna2*^{KO} mice, which have potentiated and impaired nicotine-facilitated CA1 hippocampal synaptic plasticity, respectively. The findings support the hypothesis that $\alpha 2^*$ nAChRs influence hippocampus-dependent learning and memory via alterations in nicotine-facilitated CA1 hippocampal synaptic plasticity in adolescent mice (Fig. 9). These effects were not influenced by locomotor (hyperactivity), sensory (pain response), or anxiety-related measures (center time); which suggests that our learning and memory observations are not confounded by modifications in other types of behaviors.

The $\alpha 2$ nAChR subunits are expressed on GABAergic OLM interneurons in the stratum oriens (SO) of the CA1 of the mouse (Nakauchi et al. 2007; Leao et al. 2012). These OLM cells are anatomically positioned such that they can regulate neurotransmitter release and local circuit activity. Activation of these neurons

Figure 6. Stereotypic behaviors were assessed in wild-type and *Chrna2*^{KO} mice on day 1. Results illustrated that stereotypic behaviors do not differ based on drug treatment or genotype. $N = 5-8$ per group.

Figure 7. Deficits in *Chrna2*^{KO} adolescent mice were observed on the preexposure-dependent contextual fear conditioning paradigm. As a measure of conditioning, we examined changes in individual animals freezing from day 1 (preexposure) to day 3 (context test) using matched-pair t-tests. (A) day 1 to day 3 analysis illustrated that all mice condition (i.e., have significant enhancement of freezing behavior on day 3 versus day 1), independent of genotype or drug treatment. (*) $P = 0.048$, Bonferroni-corrected, (**) $P = 0.01$, Bonferroni-corrected, (***) $P = 0.004$, Bonferroni-corrected, $N = 5-8$ per group. On contextual testing day (day 3, CT), *Chrna2*^{KO} mice had reduced freezing behavior, independent of drug treatment. $N = 5-8$ per group, (*) $P = 0.02$. (B) For day 2 (IS), post hoc analysis revealed that wild-type nicotine-treated mice had significantly greater freezing behavior than nicotine-treated *Chrna2*^{KO} mice. Bonferroni-corrected, $N = 11-14$ per group, (*) $P = 0.02$.

demonstrates that they can regulate long-term potentiation via GABA release (Leao et al. 2012). Interestingly, 50% or more of the OLM ^{$\alpha 2$} neurons are somatostatin (SOM) positive neurons within the SO of the CA1 (Jia et al. 2010; Leao et al. 2012), highlighting that the *Chrna2*-positive neurons may represent a distinct molecular genetic target within the hippocampus (Leao et al. 2012). Optogenetic studies using blue light activation of OLM ^{$\alpha 2$} cells expressing channelrhodopsin in *Chrna2*-Cre mice, confirm that these GABAergic interneurons influence long-term potentiation within the CA1 hippocampus through GABAergic release (Leao et al. 2012). Based on these findings, our current results provide additional evidence for the hypothesis that $\alpha 2$ nAChR subunit assemblies within the OLM ^{$\alpha 2$} CA1 hippocampal brain region have functional consequences in synaptic plasticity, which may underlie hippocampus-dependent learning and memory in mice (Kleeman et al. 2016).

Previous studies have demonstrated that deletion of the $\alpha 2$ nAChR subunit results in enhancements in the acquisition of intravenous nicotine self-administration (in the first 2 d after transitioning from food reinforcement), context dependent nicotine withdrawal, sex-dependent nicotine-facilitated fear conditioning (Lotfipour et al. 2013), and hippocampus-dependent memory impairments (Kleeman et al. 2016). Using a dorsal hippocampus-dependent behavioral task, known as the preexposure-dependent contextual fear conditioning, we extended these results and demonstrated that adolescent male hypersensitive $\alpha 2$ nAChR subunit mutant mice displayed baseline deficits in hippocampus-dependent learning and memory. Acute low-dose nicotine exposure (0.09 mg/kg, i.p.; equivalent to blood plasma levels reached by an average cigarette (~10 ng/mL) (Portugal et al. 2012)) rescued learning and memory deficits during adolescence in the hypersensitive $\alpha 2$ nAChR mice. The result confirms that modifications in the $\alpha 2$ nAChR subunit induced functional

changes in hippocampus-dependent learning and memory during adolescence. Based on the in vivo electrophysiology studies in the *Chrna2*^{L9S/L9S} mutant mouse line, we did not predict that baseline behavior would be different, as we found no significant differences between slices from control and *Chrna2*^{L9S/L9S} mice in the stimulus-response relationships (Fig. 3B). When we performed the behavioral tasks, however, we observed a hippocampal deficit in saline-treated *Chrna2*^{L9S/L9S} versus wild-type mice (i.e., reduced freezing behavior), which was rescued by an acute exposure to nicotine. We propose the mechanisms mediating the nicotine-induced rescue of learning and memory are through enhanced potentiation of CA1 hippocampus-synaptic plasticity, via direct actions on GABAergic OLM ^{$\alpha 2$} neurons. Alternatively, the increase in freezing may be due to excessive plasticity in response to nicotine. Future studies are needed to assess the mechanisms mediating the baseline deficit in hippocampus-dependent learning in *Chrna2*^{L9S/L9S} and *Chrna2*^{KO} mice. We speculate this may be mediated via alterations in cholinergic tone, induced by enhanced or absent activity within $\alpha 2$ -containing GABAergic interneurons.

The alteration in activity may influence medial septum and/or CA1 hippocampal OLM ^{$\alpha 2$} neurons that regulate fimbria fornix septal-cholinergic input, thereby disrupting learning and memory (Ishii et al. 2005; Lovett-Barron et al. 2014). The hypothesis is derived from studies illustrating that dendritic inhibition of hippocampal neurons influence fear memory (Lovett-Barron et al. 2014).

The interpretation of our learning and memory results is based on assessing freezing behavior on days 2 and 3 using the preexposure-dependent contextual fear conditioning paradigm. A failure to exhibit enhanced freezing on days 2 and 3 is likely due to the inability to acquire appropriate contextual representations during preexposure day 1. In our results, greater variability in freezing behavior was observed on day 2 after immediate-shock versus day 3 of contextual testing in *Chrna2*^{L9S/L9S} and *Chrna2*^{KO} mice. Previous studies using alcohol demonstrated that day 2 freezing behavior does not always predict day 3 freezing data (Cushman et al. 2011). While alcohol was able to reduce freezing on day 2 after an immediate-shock, it had no effect on day 3. The findings highlight that alcohol may impair the mechanisms mediating pattern completion in the presence of an immediate-shock; this deficit is not present during pattern completion of the shock-context pairing on day 3. Pattern completion refers to the ability of the hippocampus to use a subset of features experienced previously to recall or activate a conjunctive representation (Rudy et al. 2002, 2004; Matus-Amat et al. 2004; Nakashiba et al. 2012). In our current analysis, we did not observe a matched-pair correlation between days 2 and 3 freezing behavior in *Chrna2*^{L9S/L9S} and *Chrna2*^{KO} mice. The data confirmed that freezing behavior on day 2 did not predict freezing on day 3. The prior results with alcohol are in contrast with our current study, which illustrate that behavioral deficits are more prevalent on day 3 of contextual testing. This is likely due to a difference in methods, i.e., alcohol versus nicotine treatment.

Figure 8. Locomotor (rearing/vertical, mid-line crosses/vertical, automated vertical/horizontal), anxiety (center/perimeter time), and sensory response (shock reactivity) were assessed in wild-type littermate control and *Chrna2*^{KO} mice. Behaviors were assessed in the contextual fear conditioning chamber during the preexposure period on day 1 (PE, Fig. 8A). Shock reactivity was assessed on day 2 (IS, Fig. 8A) using the Med Associated Automated video tracking system. (A) For rearing behavior, no main effects or interactions were observed, although there was a trend for an interaction. $N = 5-8$ per group. (B) For mid-line crosses, *Chrna2*^{KO} versus wild-type littermate control mice exhibit enhanced activity on day 1, independent of drug treatment, $N = 11-14$ per group, $(^{**}) P = 0.01$. (C-E) For anxiety, center (C) or perimeter time (D) did not differ in *Chrna2*^{KO} versus wild-type littermate control mice, independent of drug treatment. $N = 11-14$ per group. (E) For automated locomotor activity, *Chrna2*^{KO} versus wild-type littermate control mice exhibit enhanced automated activity on day 1, independent of drug treatment, $N = 11-14$ per group, $(^{**}) P = 0.01$. (F) For sensory response (shock reactivity), Bonferroni-corrected t -test post hoc analysis demonstrated that *Chrna2*^{KO} versus wild-type mice did not exhibit any differences in shock reactivity on day 2 with or without drug treatment, $N = 5-8$ per group.

For studies performed in the absence of a preexposure day 1, zero to minimal freezing behavior (i.e., immediate-shock deficit) is regularly observed post-shock, illustrating a deficit in contextual encoding. In the presence of preexposure day 1, a rescue of the immediate-shock deficit is observed, associated with a significant enhancement of freezing behavior post-shock. The findings highlight that preexposure to a context develops a conjunctive representation of that environment which can be recalled on immediate-shock day to enhance freezing behavior (Rudy et al. 2002). In the current analysis, enhanced freezing behavior ($>15\%$) was observed on day 2 in *Chrna2*^{L9/S/L9/S} and *Chrna2*^{KO} mice and their wild-type littermate control mice. The only exception was minimal freezing behavior on day 2 of nicotine-treated *Chrna2*^{KO} mice. For all but one group, the data suggest that the immediate-shock deficit has been rescued in these mice given preexposure day 1. Therefore, the formation of a conjunctive representation of the context was observed in all groups, except for nicotine-treated *Chrna2*^{KO} mice. This would suggest that the ability of a subset of features to activate a conjunctive representation in the presence of a shock (i.e., pattern completion) is normal in *Chrna2*^{KO} and *Chrna2*^{L9/S/L9/S} mice, with the exception of nicotine-treated *Chrna2*^{KO} mice (Rudy et al. 2002). However, when memory of the shock-context pairing was tested on day 3, a deficit in freezing behavior was observed in saline-treated *Chrna2*^{L9/S/L9/S} and all *Chrna2*^{KO} mice. Thus, we have reason to believe that shock-context memory is altered by $\alpha 2^*$ nAChRs (Rudy et al. 2002, 2004; Matus-Amat et al. 2004). Prior results have demonstrated that *Chrna2*^{KO} mice exhibit deficits in hippocampus-dependent memory (Kleeman et al. 2016). Thus, in combination

with current results, day 3 data appear to best represent further evidence that $\alpha 2^*$ nAChRs are important in hippocampus-dependent learning and memory. We speculate that the deficits observed on day 3 versus day 2 are mediated through mechanisms that relate to more permanent memory traces (Frankland et al. 2001).

Please note, in supplementary studies, we have assessed the impacts of preexposure on the contextual fear conditioning procedure in adolescent wild-type and *Chrna2*^{KO} mice (S Lotfipour et al., in prep.). The methods used for the no preexposure control group were similar to those described in our article, except animals were not given the 10-min preexposure on day 1. Based on previous studies (Cushman et al. 2011), we predicted and observed that animals in the no preexposure control group would fail to exhibit freezing behavior post-shock (day 2) and show minimal increase ($<10\%$) on context test (day 3). The findings help validate our preexposure model used in our current studies. We have not included these data in the current article as they are integrated in a supplemental study.

We believe our effects demonstrate direct hippocampus-dependent learning memory modifications rather than indirect effects (e.g., locomotor hyperactivity, sensory, or anxiety-related behaviors). When we measured exploratory behavior in the adolescent hypersensitive *Chrna2*^{L9/S/L9/S} and *Chrna2*^{KO} mice, our results demonstrated that the mutant mice have heightened activity. If hyperactivity on day 1 was confounding learning and memory deficits on day 3, we predicted that nicotine-treated *Chrna2*^{L9/S/L9/S} or *Chrna2*^{KO} mice independent of nicotine treatment, would illustrate significant association between hyperactivity and freezing behavior. When *Chrna2*^{L9/S/L9/S}, *Chrna2*^{KO} or their wild-type littermate control mice were separated by treatments and/or genotype, activity on day 1 did not predict freezing behavior on day 3. Given that the results did not illustrate selective correlations in nicotine-treated *Chrna2*^{L9/S/L9/S} or *Chrna2*^{KO} mice independent of nicotine treatment, we conclude that hyperactivity on day 1 does not confound interpretations in our learning and memory results on day 3. Indeed, the hyperactivity that is induced by dorsal hippocampal lesions has been argued to result from the same learning impairment that disrupts contextual learning: impaired ability to encode the multisensory features of the environment into a stable contextual representation, i.e., the “common-deficit hypothesis” (Godsil et al. 2005). Further exploration is needed on whether similar mechanisms as proposed by Godsil and colleagues may be influencing our results. Prior results have demonstrated that *Chrna2*^{KO} mice exhibit deficits in hippocampus-dependent memory (Kleeman et al. 2016). Thus, our findings fit well with recent data in the *Chrna2*^{KO} mice as assessed via an alternative behavioral task, i.e., the object location but not the hippocampus-independent novel object recognition task (Kleeman et al. 2016). If locomotor modifications confound learning and memory deficits, we would predict that both behaviors would be altered in *Chrna2*^{KO} mice, which was not observed.

Figure 9. Electrophysiological and behavioral phenotypes of wild-type, *Chrna2*^{KO} and *Chrna2*^{L9S/L9S} mice. The findings indicate that $\alpha 2^*$ nAChRs are capable of participating in nicotinic facilitation of long-term potentiation in the hippocampal CA1 and influence the effects of nicotine on hippocampus-dependent learning and memory.

Thus, we conclude that the hippocampus-dependent learning and memory observations in the current studies were not confounded by modifications in locomotor hyperactivity.

Our data also suggest that our learning and memory results are not influenced by changes in sensory response (i.e., pain sensitivity as determined by shock reactivity) or anxiety-related behavior (center time). The preexposure-dependent contextual fear procedure was specifically designed to minimize any potential analgesic effects of memory modulating drugs by separating drug administration from shock presentation. For sensory response, we observed increased shock reactivity in *Chrna2*^{L9S/L9S} mice, independent of drug exposure. If increased shock reactivity is a measure of enhanced sensory response, we would predict increased freezing behavior during contextual testing in saline-treated *Chrna2*^{L9S/L9S} mice; rather, we observed a decrease in freezing behavior. No significant effects were observed for shock reactivity in *Chrna2*^{KO} mutant mice. Thus, our findings argue that altered sensory response cannot explain changes in freezing behavior. Previous studies in adult *Chrna2*^{KO} mice have indicated differences in nicotine-induced hyperalgesia in the hotplate test, but not when assessing baseline or nicotine-induced analgesia to the tail withdrawal or the formalin test (Lotfipour et al. 2013). The findings suggest that nicotine-induced pain response to selective behaviors may be influenced in *Chrna2*^{KO} and *Chrna2*^{L9S/L9S} mice. However, given that (i) our nicotine exposure did not occur during day 2 immediate-shock presentation, (ii) adolescent *Chrna2*^{KO} mice did not exhibit significant differences in shock reactivity, and (iii) *Chrna2*^{L9S/L9S} mice had increased shock reactivity with reduced (instead of increased) freezing behavior in saline-treated mice, we do not believe that pain sensitivity is a plausible explanation of our results. In regards to anxiety-related behaviors, our current studies did not observe differences in center time in *Chrna2*^{L9S/L9S} or *Chrna2*^{KO} mice. Given that ventral (versus dorsal) hippocampal circuits are more involved in mediating anxiety-related behaviors and we did not observe differences in center time, we are confident that our results are not confounded by changes in anxiety-related circuits. Therefore, indirect effects, including sensory response to shock or anxiety, do not appear to account for our findings. Rather they implicate learning and memory processes. Our findings are consistent with previous studies, which found that hippocampal nAChR antagonists disrupt nicotine-facilitated learning and memory processing, as tested by contextual fear conditioning (Davis et al. 2007). Furthermore, genetic studies have demonstrated an absence of nicotine-facilitated contextual fear conditioning in $\beta 2^{-/-}$ (but not $\alpha 7^{-/-}$, $\beta 3^{-/-}$, or $\beta 4^{-/-}$) mutant mice (Wehner et al. 2004; Davis and Gould 2007; Semenova et al. 2012). Such findings sug-

gest that nAChRs assembled from select subunits regulate nicotine's effects on learning and memory processing.

Our results are not without limitations. For example, authors have argued that nAChR expression and/or function in oocytes may not be identical to native tissues (Buller and White 1990; Sivilotti et al. 1997). In particular, differences in nAChR subunit composition and/or molar concentrations of individual subunits are known to influence "channel open times, ion conductance, desensitization rates" as well as the "sensitivity to agonists and antagonists" (Boulter et al. 1987; Deneris et al. 1988; Wada et al. 1988; Papke et al. 1989; Luetje and Patrick 1991; Paradiso et al. 2001; Grady et al. 2007; Lipovsek et al. 2008; McIntosh et al. 2009; Jin and Steinbach 2011, 2015). Neurons in animal and human studies contain a diversity of neuronal α/β nAChR subunits at different levels, which would differently alter the subunit composition and stoichiometry. For example, interneurons of the stratum oriens (where OLM neurons reside) contain more than $\alpha 2$ and $\beta 2$ nAChR subtypes (Sudweeks and Yakel 2000; Jia et al. 2009). Thus, applicability of our studies in oocytes to function in neurons in vivo needs to be interpreted cautiously. Our studies in oocytes were applied only as an initial screen to confirm the functionality of the serine for a leucine (L9/S) substitution in the $\alpha 2$ nAChR subunit. Future studies could use, for example, single-cell electrophysiology and neurotransmitter release assays or in vivo imaging coupled with behavioral techniques to better confirm the biophysical and pharmacological properties of the hyper-sensitive nAChR in *Chrna2*^{L9S/L9S} mice (Sudweeks and Yakel 2000; Grady et al. 2007; Jia et al. 2009; Lovett-Barron et al. 2014). Another potential limitation authors have reported regarding oocytes studies is the possibility of low level endogenous expression of peripheral $\alpha 1$ nAChR subunits (Buller and White 1990). Such a finding will not have an impact in our studies, given that neuronal $\alpha 2$ or $\beta 2$ nAChR subunits when expressed, alone, in oocytes do not form functional nAChRs (Boulter et al. 1987; Deneris et al. 1988; Wada et al. 1988). Prior work has used similar oocyte expression methodologies assessing knock-in mutations for different nAChRs to validate behavioral outcomes in mice and humans (Lester et al. 2003; Klaassen et al. 2006; Lipovsek et al. 2008). Thus, the oocyte expression studies have been helpful in identifying function in vivo, with our current studies providing supportive evidence for their validation.

In addition to limitations on oocyte studies, other concerns should be highlighted. In particular, heightened expression of $\alpha 2^*$ nAChRs appear during the first 2 wk of rodent life, while our behavioral and electrophysiological studies took place during adolescence (i.e., 4 wk of life). Therefore, learning and memory modifications induced by developmental nicotine exposure could

be potentiated if nicotine was delivered during this heightened period of expression during the first weeks of early postnatal development. Furthermore, it is possible that *Chrna2*^{L9'S/L9'S} mice have modified $\alpha 2^*$ nAChRs expression patterns within the brain, particularly since prior results demonstrate that knock-in mutations within the TM2 may decrease receptor expression, but not mRNA levels (O'Neill et al. 2013). Therefore, future studies should aim to determine whether the *Chrna2*^{L9'S/L9'S} mice exhibit differences in nAChR binding within the brain. Given the selectivity of $\alpha 2^*$ nAChRs within the stratum oriens GABAergic OLM interneurons, it is possible that such effects may be negligible in the dorsal hippocampal CA1. Prior studies have demonstrated that maternal nicotine exposure does reduce the number of $\alpha 2^*$ cells and $\alpha 2$ nAChR subunit mRNA expression by 10%–15% in the dorsal hippocampal CA1, i.e., one brain region where the current electrophysiological slice recording took place in the current study (Chen et al. 2016). Therefore, it is possible that similar effects would be observed within the *Chrna2*^{L9'S/L9'S} mice, with likely more significant consequences observed within the ventral (versus dorsal) hippocampus (Chen et al. 2016). Given our anxiety results, we do not believe that ventral hippocampus nAChRs would confound interpretation of our current findings. Indeed, we found no significant differences between slices from control and *Chrna2*^{L9'S/L9'S} mice in the stimulus–response relationships in our electrophysiological studies within the dorsal/intermediate CA1 hippocampus (Fig. 3B), suggesting that the modified expression of $\alpha 2^*$ nAChRs had no significant effect on basal synaptic transmission at the SC pathway.

Another limitation of our current studies is that we have not assessed sex-dependent effects. Given prior findings that emotional memory processing is modified in a sex-dependent manner in adult *Chrna2*^{KO} mice (Lotfipour et al. 2013), future studies should assess sex-dependent effects in hippocampal-dependent learning and memory in adolescent *Chrna2*^{KO} and *Chrna2*^{L9'S/L9'S} mice. In addition, future studies should assess nicotine dose–response relationships and age-dependent effects using the *Chrna2*^{KO} and *Chrna2*^{L9'S/L9'S} mice. Our current results used the 0.09 mg/kg/injection nicotine dose based on adult data illustrating enhancement in wild-type mice (Kenney and Gould 2008; Kutlu et al. 2016). Therefore, we were initially surprised that 0.09 mg/kg/injection had no effects in wild-type mice. Subsequent studies, however, confirmed our findings in adolescent C57BL/6J mice using the 0.09 mg/kg/injection nicotine dose (Kutlu et al. 2016). Kutlu et al. (2016), have performed a nicotine dose response during adolescence and adulthood using the preexposure-dependent contextual fear conditioning paradigm. They have demonstrated that adolescent C57BL/6J wild-type mice are less sensitive to low-dose nicotine exposure, at the 0.09 mg/kg dose, which we have replicated with our findings in adolescent wild-type mice.

Our findings illustrated that while low-dose nicotine exposure had no effect on adolescent wild-type mice, as reported (Kutlu et al. 2016), nicotine exposure was able to rescue the baseline deficit in *Chrna2*^{L9'S/L9'S}, but not *Chrna2*^{KO} mice. The findings support the rationale that the hypersensitive mutation potentiated synaptic plasticity in addition to hippocampus-dependent learning and memory at nicotine doses that did not influence wild-type mice. Given that nicotine pretreatment was not able to rescue the baseline deficit in hippocampal-dependent learning and memory in *Chrna2*^{KO} mice, we propose that this was mediated by the known absence of nicotine-facilitated synaptic plasticity (Nakauchi et al. 2007). Thus, nicotine-facilitated synaptic plasticity plays an important role in how nicotine can rescue baseline deficits in learning and memory. Whether these results remain at higher doses of nicotine needs to be tested in future studies. Because the *Chrna2*^{KO} mice were backcrossed for >12 generations

(>99.98% of the percentage of the C57BL/6J host strain) while the *Chrna2*^{L9'S/L9'S} mice were backcrossed for significantly fewer generations ($N = 3$ –4, 75%–87.5% of C57BL/6J host strain), the reader is cautioned to the interpretations made when comparing and contrasting the effects of L9'S with those of the null mutation (% host strain attained from Fox and Witham 1997).

Materials and Methods

All animal procedures were conducted in accordance with the National Institute of Health Guide for the care and use of laboratory animals and with protocols approved by the Institutional Animal Care and Use Committee at the University of California, Los Angeles and Irvine. Mice used in this study were placed on a 12-h dark–light cycle with ad lib access to food and water. Mice were group housed and tested during the light phase of the light cycle.

Animals

Construction and characterization of the *Chrna2* null mutant mouse line (backcrossed to C57BL/6J, N17–18 generations, RRID:MGI_3790875) were described earlier (Lotfipour et al. 2013). *Chrna2*^{L9'S/WT} mice (backcrossed to C57BL/6J, N3–4 generations) were engineered similar to (Taranda et al. 2009), with the exception that (i) an FRT flanked positive selection marker phosphoglycerate kinase gene promoter-neomycin resistance (PGK-NEO) cassette was inserted within an AgeI restriction enzyme genomic site, upstream of the fifth exon of the *Chrna2* gene (Fig. 1A) and (ii) a gene synthesized (GENWIZ) Aat II/NdeI segment of DNA with a modified AGC codon for Serine corresponding to the 9' amino acid within the transmembrane region 2 (TM2) (Revah et al. 1991; Labarca et al. 1995; Lester et al. 2003; Tapper et al. 2004; Piazas et al. 2005; Drenan et al. 2008) was inserted within the 5th exon of the *Chrna2* gene (Fig. 1; Klaassen et al. 2006). The targeting vector was electroporated into SvJ129 embryonic stem (ES) cells and homologous recombinants were confirmed through DNA sequencing (Fig. 1B) and Southern blot (Fig. 1C) using a XmnI/NheI 1007 base pair fragment upstream of exon 1. Genomic DNA from electroporated ES cells were cut with BstZ17I/SwaI restriction enzymes with a targeted Southern blot fragment of 9500 bp (Fig. 1C). Targeting efficiency of homologous recombination within ES cells was calculated at 43% (31 of 72 ES cells had the targeted fragment). Targeted ES cells were microinjected into C57BL/6J blastocyst embryos at the UCLA Transgenic Core and implanted into pseudopregnant female mice. Germline transmitted agouti colored offspring were DNA sequenced at the UCLA genomic core to confirm that they were carriers of the AGC/CTC heterozygous genomic modification within exon 5 (Fig. 1B). The introduction of the AGC site at the correct location within the fifth exon introduced a SacI restriction enzyme site, which acted as a quick screening strategy for confirmation of the genetic mutation (not shown). After confirming the presence of the mutation and the correct orientation of the FRT flanked PGK-NEO cassette, the mice were mated with congenic FLPeR mice (#009086, The Jackson Laboratory) to delete the positive selection marker, leaving a 34-bp FRT finger print in the intronic genomic region. PCR primers (A2L9S_1.10) GGCTAGTCAGAACAGCTGCATT and (A2L9S_1.11) GAACAAGGAAGAAATCGGCAGG (Eurofins MWG Operon LLC) were designed upstream of and downstream from the deleted PGK-NEO cassette (Fig. 1A) to provide PCR-amplified fragments for wild-type and mutant carriers (not shown).

Oocyte expression studies

The use of oocyte expression studies (Fig. 3A) was applied as an initial screen to determine the functionality of a substitution of a serine for a leucine (L9'S) in the $\alpha 2$ nAChR subunit. Nicotinic receptor subunits were subcloned into a pSGEM vector, which contains *Xenopus* 5'-UTR and 3'-UTR segments that markedly increase expression of cloned cDNAs (Liman et al. 1992; Lipovsek et al.

2008). Plasmid constructs, where the L9' amino acid (located in TM2) was replaced either with serine, threonine, or alanine, were linearized with Nhe I to generate templates for in vitro transcription. cRNA prepared from wild-type mouse $\alpha 2$ plasmid, as well as the mutants L9'S, L9'A, and L9'T mutants, were coinjected in oocytes along with the wild-type mouse $\beta 2$ cRNA at a 1:1 equimolar ratio (Fig. 3A). Electrophysiological recordings and concentration–response curves to ACh were performed under two-electrode voltage clamp, as described in Lipovsek et al. (2008).

Hippocampal synaptic plasticity studies

Slice preparation and extracellular field recordings within the dorsal/intermediate CA1 hippocampal slice were performed using the methods described by Nakauchi et al. (2007), Figure 3B–F. Briefly, slices of 375–400 μ m were attained from 15 wild-type and *Chrna2*^{L9'S/L9'S} adolescent mice (4 wk of age). Animals included in the study were: (i) C57BL/6J wild-type male mice ($n = 5$), (ii) *Chrna2*^{L9'S/L9'S} male ($n = 5$) homozygous S9'S mice, (iii) *Chrna2*^{L9'S/L9'S} wild-type male ($n = 3$) and female ($n = 2$) mice, with the reported “ n ” representing the numbers of experiments in our study. Slices from these animals were maintained in artificial cerebral spinal fluid at 30°C, containing (mM): NaCl, 124; KCl, 5; NaH₂PO₄, 1.25; MgSO₄, 2; CaCl₂, 2.5; NaHCO₃, 22; and glucose, 10, and oxygenated with 95% O₂ and 5% CO₂. A stimulating electrode activated the glutamatergic stratum radiatum schaffer collateral projections arriving from the CA3 hippocampus. Field excitatory postsynaptic potentials (fEPSPs) were recorded within the stratum radiatum using a glass electrode filled with 2 M NaCl (3–8 M Ω). We monitored LTP induction at the SC pathway using a subthreshold stimulation protocol (weak θ burst stimulation (TBS): two θ bursts of four pulses at 100 Hz), which induces LTP in the presence, but not absence, of the activation of $\alpha 2^*$ -nAChR-expressing O/A interneurons (Nakauchi et al. 2007). To evaluate the magnitudes of LTP, the mean value for the slopes of fEPSPs recorded 50–60 min after weak TBS was calculated and expressed as a ratio of the mean value of the initial baseline slope of fEPSPs. For the hippocampal synaptic plasticity studies, we used two subthreshold doses of nicotine (0.01 and 0.1 μ M) to assess nicotinic facilitation of LTP. The rationale for the use of the subthreshold doses was based on the observation that our systemic nicotine treatments, at the 0.09 mg/kg/injection dose, were subthreshold to influence learning and memory in wild-type mice, but not in the *Chrna2*^{L9'S/L9'S} mice. The majority of brain tissue slices from individual animals ($n = 9$) were exposed to all vehicle and drug conditions, with a few individual animal brain slices exposed to drug exposures alone ($n = 2$), or additional vehicle ($n = 3$) and/or drug exposures ($n = 3$).

Nicotine studies in adolescent mice using the preexposure-dependent contextual fear conditioning procedure

Male adolescent (4 wk of age) *Chrna2*^{KO}, *Chrna2*^{L9'S/L9'S} or wild-type littermate control mice of each respective line were used in the current studies. Importantly, *Chrna2*^{WT} mice used for the *Chrna2*^{L9'S/L9'S} studies were littermates of the *Chrna2*^{L9'S/L9'S} mice. Similarly, *Chrna2*^{WT} mice used for the *Chrna2*^{KO} studies were littermates of the *Chrna2*^{KO} mice. Three days before day 1 of preexposure (Fig. 4A, PE), animals were handled and habituated to their transport cage for 5 min for 2 d, similar to Kenney and Gould (2008) and Kutlu et al. (2016). On the third day, animals were briefly weighed, exposed to their transport cage, and experiments began on the next day. On day 1 of preexposure, mice were transferred to the behavioral testing suite and allowed to acclimate to the new environment for at least 1 h prior to experimentation. Subsequently, on day 1 of preexposure, using random assignment, mice were placed into transport cages, administered either a pretraining injection of vehicle or nicotine (0.09 mg/kg, i.p., base) 3–5 min prior to being preexposed to a novel conditioning chamber for 10 min. Chamber dimensions were four identical 30 cm $\times$ 24 cm $\times$ 21 cm (Med Associates,

Inc.) boxes fitted with grid floors and a digital video camera (Fig. 4A, PE). On day 2 (Immediate-Shock, IS, Fig. 4A), mice were placed in the same chamber and within 10 sec of entry given a single electric shock (0.75 mA, 2 sec) and assessed for shock reactivity and freezing behavior post-shock (30 sec). On day 3 (Context Test, CT, Fig. 4A), mice were administered a pretesting injection of vehicle or nicotine (0.09 mg/kg, i.p.), and 3–5 min later assessed for freezing behavior in the previously shocked environment for 8 min. The nicotine dose and dual injection approach was based on the study of Kenney and Gould (2008) and the time period for PE and CT was based on the study of Cushman et al. (2011). The subthreshold dose of nicotine was previously shown to enhance learning and memory in adult wild-type mice (Kenney and Gould 2008), therefore this dose was chosen for the current studies. The time periods for these two phases are based on the fact that different processes are engaged. During the preexposure period the animals are forming a new hippocampus-dependent contextual representation of the conditioning chamber whereas on day 3 they are retrieving this representation and expressing fear based on the strength of the context–shock association. Ten minutes for the preexposure was based on prior piloting to determine the necessary length of time for the contextual representation to be formed. 8 min for the context test is based on the most commonly used length during test day (Kim and Fanselow 1992; Bissiere et al. 2011). For consistency in our analyses between day 1 and 3, only the first 8 min of the 10 min PE period is reported in our results, even though the findings remained consistent if the 10-min period was reported instead. Freezing and shock reactivity were monitored through near infrared lighting and a digital video camera recording at 30 frames per second placed in front of the chambers, and scored through a Med Associates fear conditioning software package (Med Associates Video Freeze system). This system calculates the average motion in the video as activity units, which are determined based on the amount of gray scale pixel change in the image for each frame normalized by background noise when no mouse is present. Freezing was defined as activity below 19 activity units for 1 sec (30 frames). Shock reactivity on day 2 was used as a measure of sensory pain response in the presence of a shock, as determined by the activity units measured during the 2 sec of the 0.75-mA shock and the following 2 sec. Animals which have greater shock reactivity, likely have enhanced pain sensitivity to the shock (King et al. 1996). Freezing varies positively with shock intensity and pain sensitivity, so increased pain sensitivity should increase freezing (Fanselow and Bolles 1979).

To illustrate conditioning (i.e., a significant increase in freezing on context test after shock training), freezing data were graphed together as PE (day 1) and CT (day 3). The data are visualized using the same time scale on PE (day 1) and CT (day 3) of 8 min. We separated PE/CT and IS (day 2 data) results primarily because of the different time scales used in the analysis: 8 min for PE and CT versus 30 sec for IS (Figs. 4, 7) in order to reduce confusion about the different time scales used. The results remained consistent if data were illustrated by individual day of experimentation instead.

Growth, exploratory, stereotypical, and anxiety behaviors

Animal weight was measured on the day before preexposure day 1 and on day 2 of immediate-shock. Manually scored exploratory (vertical-rearing and horizontal-midline crosses), anxiety (center and perimeter time), and stereotypical mouse behavior were quantified in the conditioning chamber, by a blind observer during the 10-min preexposure period on day 1. Manually scored exploratory behavior was assessed as a secondary measure of automated locomotor activity, as previous work had demonstrated that rearing and crosses did not individually resolve automated locomotor activity (Cushman et al. 2011). Stereotypical behaviors included natural mouse behavior observed in a novel environment, including grooming, scratching, chewing, head nodding, paw tremors, head shakes, jumping and backing behavior (Lotfipour et al. 2013). Center time was quantified by manually recording the seconds spent in the center versus parameter of the

apparatus for individual animals. An increase in center time is regarded as reduced anxiety. A mouse was defined as “in center” when its entire body was a tail length away from the nearest wall. Weight gain was used, in part, to calculate the injection volume. Weight gain and stereotypical behaviors were used to determine any growth or development modifications in adolescent *Chrna2*^{L9^S/L9^S} and *Chrna2*^{KO} mice. We assessed automated locomotor activity, rearing, mid-line crosses, center time, and shock reactivity, to determine genotype and drug-induced changes in exploratory activity, anxiety and pain sensitivity (as a measure of sensory response).

Statistics

Descriptive data were analyzed using the JMP Pro statistical software (SAS Institute Inc., version 12.0.1) and OriginPro 8.1 (OriginLab). Power analyses were determined using JMP Pro and G*Power 3.1. Electrophysiology data were assessed with *t*-test analysis and Bonferroni-corrected for multiple comparisons for each of the three doses tested. As our primary interests were within dose assessments for the electrophysiology data, across dose comparisons and multiple comparisons correction were not made. Data from wild-type mice from the C57Bl/6J and *Chrna2*^{L9^S/L9^S} line or the male and female data did not differ, thus results were pooled for analysis. Each data point collected was assessed as a separate experiment and not as a within measure analysis during *t*-test analysis. For behavioral data, day 1 versus day 3 freezing data as well as days 2 and 3 freezing data were assessed using a matched-pair within subject analysis, followed by Bonferroni-correction for all four comparisons. The association between day 1 activity and day 3 freezing data were assessed as a simple linear correlation using bivariate analysis. For day 1 stereotypical and activity data as well as days 2 and 3 freezing data, significant effects were assessed using analysis of variance (ANOVA). When there were more than two groups compared, Bonferroni-correction for multiple comparisons was applied. Outliers were determined and excluded based on Box-and-Whisker plot outlier analysis, identifying data outside the interquartile range (Tukey 1977). For the *Chrna2*^{L9^S/L9^S} mouse line, a total of four mice were identified as outliers for freezing data (the primary outcome variable) and excluded from all analyses. For the *Chrna2*^{KO} mouse line one mouse was identified as an outlier for freezing data and excluded from all analyses.

Acknowledgments

We thank Meisheng Jiang, Rong Qiao, and the UCLA Transgenic Core for their assistance on this project. We thank Ms. Anjelica Mia Cardenas for her assistance on the manuscript. This study was funded through two Brain and Behavior (formally NARSAD) Research Foundation Young Investigator Awards (21517, 17717) (S.L.), University of California Office of the President Tobacco-Related Disease Research Program Postdoctoral Fellowship (20FT-0072) and Project Grant (22RT-0103A) (S.L.), NIMH Grant MH62122 (M.S.F.), and NIDA Grant DA026458 (K.S.).

References

- Anagnostaras SG, Maren S, Fanselow MS. 1999. Temporally graded retrograde amnesia of contextual fear after hippocampal damage in rats: within-subjects examination. *J Neurosci* **19**: 1106–1114.
- Bissiere S, Zelikowsky M, Ponnusamy R, Jacobs NS, Blair HT, Fanselow MS. 2011. Electrical synapses control hippocampal contributions to fear learning and memory. *Science* **331**: 87–91.
- Boulter J, Connolly J, Deneris E, Goldman D, Heinemann S, Patrick J. 1987. Functional expression of two neuronal nicotinic acetylcholine receptors from cDNA clones identifies a gene family. *Proc Natl Acad Sci* **84**: 7763–7767.
- Buller AL, White MM. 1990. Functional acetylcholine receptors expressed in *Xenopus* oocytes after injection of Torpedo β , γ , and δ subunit RNAs are a consequence of endogenous oocyte gene expression. *Mol Pharmacol* **37**: 423–428.
- Chen K, Nakauchi S, Su H, Tanimoto S, Sumikawa K. 2016. Early postnatal nicotine exposure disrupts the $\alpha 2^*$ nicotinic acetylcholine receptor-mediated control of oriens-lacunosum moleculare cells during adolescence in rats. *Neuropharmacology* **101**: 57–67.
- Cushman JD, Moore MD, Jacobs NS, Olsen RW, Fanselow MS. 2011. Behavioral pharmacogenetic analysis on the role of the $\alpha 4$ GABA(A) receptor subunit in the ethanol-mediated impairment of hippocampus-dependent contextual learning. *Alcohol Clin Exp Res* **35**: 1948–1959.
- Davis JA, Gould TJ. 2007. $\beta 2$ subunit-containing nicotinic receptors mediate the enhancing effect of nicotine on trace cued fear conditioning in C57BL/6 mice. *Psychopharmacology (Berl)* **190**: 343–352.
- Davis JA, Kenney JW, Gould TJ. 2007. Hippocampal $\alpha 4\beta 2$ nicotinic acetylcholine receptor involvement in the enhancing effect of acute nicotine on contextual fear conditioning. *J Neurosci* **27**: 10870–10877.
- Deneris ES, Connolly J, Boulter J, Wada E, Wada K, Swanson LW, Patrick J, Heinemann S. 1988. Primary structure and expression of $\beta 2$: a novel subunit of neuronal nicotinic acetylcholine receptors. *Neuron* **1**: 45–54.
- Drenan RM, Grady SR, Whiteaker P, McClure-Begley T, McKinney S, Miwa JM, Bupp S, Heintz N, McIntosh JM, Bencherif M, et al. 2008. In vivo activation of midbrain dopamine neurons via sensitized, high-affinity $\alpha 6$ nicotinic acetylcholine receptors. *Neuron* **60**: 123–136.
- Fanselow MS. 1990. Factors governing one trial contextual conditioning. *Anim Learn Behav* **18**: 264–270.
- Fanselow MS, Bolles RC. 1979. Naloxone and shock-elicited freezing in the rat. *J Comp Physiol Psychol* **93**: 736–744.
- Fox RR, Witham BA. 1997. *Handbook on Genetically Standardized JAX Mice*. 5:60.
- Frankland PW, O'Brien C, Ohno M, Kirkwood A, Silva AJ. 2001. α -CaMKII-dependent plasticity in the cortex is required for permanent memory. *Nature* **411**: 309–313.
- Godsil BP, Stefanacci L, Fanselow MS. 2005. Bright light suppresses hyperactivity induced by excitotoxic dorsal hippocampus lesions in the rat. *Behav Neurosci* **119**: 1339–1352.
- Grady SR, Salminen O, Laverty DC, Whiteaker P, McIntosh JM, Collins AC, Marks MJ. 2007. The subtypes of nicotinic acetylcholine receptors on dopaminergic terminals of mouse striatum. *Biochem Pharmacol* **74**: 1235–1246.
- Hilscher MM, Leao RN, Edwards SJ, Leao KE, Kullander K. 2017. *Chrna2*-Martinotti cells synchronize layer 5 type A pyramidal cells via rebound excitation. *PLoS Biol* **15**: e2001392.
- Ishii K, Wong JK, Sumikawa K. 2005. Comparison of $\alpha 2$ nicotinic acetylcholine receptor subunit mRNA expression in the central nervous system of rats and mice. *J Comp Neurol* **493**: 241–260.
- Jia Y, Yamazaki Y, Nakauchi S, Sumikawa K. 2009. $\alpha 2$ nicotine receptors function as a molecular switch to continuously excite a subset of interneurons in rat hippocampal circuits. *Eur J Neurosci* **29**: 1588–1603.
- Jia Y, Yamazaki Y, Nakauchi S, Ito K, Sumikawa K. 2010. Nicotine facilitates long-term potentiation induction in oriens-lacunosum moleculare cells via Ca^{2+} entry through non- $\alpha 7$ nicotinic acetylcholine receptors. *Eur J Neurosci* **31**: 463–476.
- Jin X, Steinbach JH. 2011. A portable site: a binding element for 17β -estradiol can be placed on any subunit of a nicotinic $\alpha 4\beta 2$ receptor. *J Neurosci* **31**: 5045–5054.
- Jin X, Steinbach JH. 2015. Potentiation of neuronal nicotinic receptors by 17β -estradiol: roles of the carboxy-terminal and the amino-terminal extracellular domains. *PLoS One* **10**: e0144631.
- Kenney JW, Gould TJ. 2008. Nicotine enhances context learning but not context-shock associative learning. *Behav Neurosci* **122**: 1158–1165.
- Kim JJ, Fanselow MS. 1992. Modality-specific retrograde amnesia of fear. *Science* **256**: 675–677.
- King TE, Joynes RL, Meagher MW, Grau JW. 1996. Impact of shock on pain reactivity: II. Evidence for enhanced pain. *J Exp Psychol Anim Behav Process* **22**: 265–278.
- Klaassen A, Glykys J, Maguire J, Labarca C, Mody I, Boulter J. 2006. Seizures and enhanced cortical GABAergic inhibition in two mouse models of human autosomal dominant nocturnal frontal lobe epilepsy. *Proc Natl Acad Sci* **103**: 19152–19157.
- Kleeman E, Nakauchi S, Su H, Dang R, Wood MA, Sumikawa K. 2016. Impaired function of $\alpha 2$ -containing nicotinic acetylcholine receptors on oriens-lacunosum moleculare cells causes hippocampus-dependent memory impairments. *Neurobiol Learn Mem* **136**: 13–20.
- Kutlu MG, Braak DC, Tumolo JM, Gould TJ. 2016. Adolescent mice are less sensitive to the effects of acute nicotine on context preexposure than adults. *Brain Res* **1642**: 445–451.
- Labarca C, Nowak MW, Zhang H, Tang L, Deshpande P, Lester HA. 1995. Channel gating governed symmetrically by conserved leucine residues in the M2 domain of nicotinic receptors. *Nature* **376**: 514–516.
- Leao RN, Mikulovic S, Leao KE, Munguba H, Gezelius H, Enjin A, Patra K, Eriksson A, Loew LM, Tort AB, et al. 2012. OLM interneurons differentially modulate CA3 and entorhinal inputs to hippocampal CA1 neurons. *Nat Neurosci* **15**: 1524–1530.

- Lester HA, Fonck C, Tapper AR, McKinney S, Damaj MI, Balogh S, Owens J, Wehner JM, Collins AC, Labarca C. 2003. Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action. *Curr Opin Drug Discov Devel* **6**: 633–639.
- Liman ER, Tytgat J, Hess P. 1992. Subunit stoichiometry of a mammalian K^+ channel determined by construction of multimeric cDNAs. *Neuron* **9**: 861–871.
- Lipovsek M, Plazas P, Savino J, Klaassen A, Boulter J, Elgoyhen AB, Katz E. 2008. Properties of mutated murine $\alpha 4\beta 2$ nicotinic receptors linked to partial epilepsy. *Neurosci Lett* **434**: 165–169.
- Lotfipour S, Byun JS, Leach P, Fowler CD, Murphy NP, Kenny PJ, Gould TJ, Boulter J. 2013. Targeted deletion of the mouse $\alpha 2$ nicotinic acetylcholine receptor subunit gene (*Chrna2*) potentiates nicotine-modulated behaviors. *J Neurosci* **33**: 7728–7741.
- Lovett-Barron M, Kaifosh P, Kheirbek MA, Danielson N, Zaremba JD, Reardon TR, Turi GF, Hen R, Zemelman BV, Losonczy A. 2014. Dendritic inhibition in the hippocampus supports fear learning. *Science* **343**: 857–863.
- Luetje CW, Patrick J. 1991. Both α - and β -subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. *J Neurosci* **11**: 837–845.
- Matus-Amat P, Higgins EA, Barrientos RM, Rudy JW. 2004. The role of the dorsal hippocampus in the acquisition and retrieval of context memory representations. *J Neurosci* **24**: 2431–2439.
- McIntosh JM, Absalom N, Chebib M, Elgoyhen AB, Vincler M. 2009. $\alpha 9$ nicotinic acetylcholine receptors and the treatment of pain. *Biochem Pharmacol* **78**: 693–702.
- Nakashiba T, Cushman JD, Pelkey KA, Renaudineau S, Buhl DL, McHugh TJ, Rodriguez Barrera V, Chittajallu R, Iwamoto KS, McBain CJ, et al. 2012. Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. *Cell* **149**: 188–201.
- Nakauchi S, Brennan RJ, Boulter J, Sumikawa K. 2007. Nicotine gates long-term potentiation in the hippocampal CA1 region via the activation of $\alpha 2^*$ nicotinic ACh receptors. *Eur J Neurosci* **25**: 2666–2681.
- Nakauchi S, Malvaez M, Su H, Kleeman E, Dang R, Wood MA, Sumikawa K. 2015. Early postnatal nicotine exposure causes hippocampus-dependent memory impairments in adolescent mice: association with altered nicotinic cholinergic modulation of LTP, but not impaired LTP. *Neurobiol Learn Mem* **118**: 178–188.
- O'Neill HC, Lavery DC, Patzlaff NE, Cohen BN, Fonck C, McKinney S, McIntosh JM, Lindstrom JM, Lester HA, Grady SR, et al. 2013. Mice expressing the ADNFLE valine 287 leucine mutation of the $\beta 2$ nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function. *Pharmacol Biochem Behav* **103**: 603–621.
- Papke RL, Boulter J, Patrick J, Heinemann S. 1989. Single-channel currents of rat neuronal nicotinic acetylcholine receptors expressed in *Xenopus* oocytes. *Neuron* **3**: 589–596.
- Paradiso K, Zhang J, Steinbach JH. 2001. The C terminus of the human nicotinic $\alpha 4\beta 2$ receptor forms a binding site required for potentiation by an estrogenic steroid. *J Neurosci* **21**: 6561–6568.
- Plazas PV, De Rosa MJ, Gomez-Casati ME, Verbitsky M, Weisstaub N, Katz E, Bouzat C, Elgoyhen AB. 2005. Key roles of hydrophobic rings of TM2 in gating of the $\alpha 9\alpha 10$ nicotinic cholinergic receptor. *Br J Pharmacol* **145**: 963–974.
- Portugal GS, Wilkinson DS, Kenney JW, Sullivan C, Gould TJ. 2012. Strain-dependent effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. *Behav Genet* **42**: 133–150.
- Revah F, Bertrand D, Galzi JL, Devillers-Thiery A, Mulle C, Hussy N, Bertrand S, Ballivet M, Changeux JP. 1991. Mutations in the channel domain alter desensitization of a neuronal nicotinic receptor. *Nature* **353**: 846–849.
- Rudy JW, Barrientos RM, O'Reilly RC. 2002. Hippocampal formation supports conditioning to memory of a context. *Behav Neurosci* **116**: 530–538.
- Rudy JW, Huff NC, Matus-Amat P. 2004. Understanding contextual fear conditioning: insights from a two-process model. *Neurosci Biobehav Rev* **28**: 675–685.
- Salas R, Sturm R, Boulter J, De Biasi M. 2009. Nicotinic receptors in the habenulo-interpeduncular system are necessary for nicotine withdrawal in mice. *J Neurosci* **29**: 3014–3018.
- Semenova S, Contet C, Roberts AJ, Markou A. 2012. Mice lacking the $\beta 4$ subunit of the nicotinic acetylcholine receptor show memory deficits, altered anxiety- and depression-like behavior, and diminished nicotine-induced analgesia. *Nicotine Tob Res* **14**: 1346–1355.
- Sivilotti LG, McNeil DK, Lewis TM, Nassar MA, Schoepfer R, Colquhoun D. 1997. Recombinant nicotinic receptors, expressed in *Xenopus* oocytes, do not resemble native rat sympathetic ganglion receptors in single-channel behaviour. *J Physiol* **500**: 123–138.
- Son JH, Winzer-Serhan UH. 2006. Postnatal expression of $\alpha 2$ nicotinic acetylcholine receptor subunit mRNA in developing cortex and hippocampus. *J Chem Neuroanat* **32**: 179–190.
- Stote DL, Fanselow MS. 2004. NMDA receptor modulation of incidental learning in Pavlovian context conditioning. *Behav Neurosci* **118**: 253–257.
- Sudweeks SN, Yakel JL. 2000. Functional and molecular characterization of neuronal nicotinic ACh receptors in rat CA1 hippocampal neurons. *J Physiol* **527**(Pt 3): 515–528.
- Taranda J, Maisson SF, Ballesterio JA, Katz E, Savino J, Vetter DE, Boulter J, Liberman MC, Fuchs PA, Elgoyhen AB. 2009. A point mutation in the hair cell nicotinic cholinergic receptor prolongs cochlear inhibition and enhances noise protection. *PLoS Biol* **7**: e18.
- Tapper AR, McKinney SL, Nashmi R, Schwarz J, Deshpande P, Labarca C, Whiteaker P, Marks MJ, Collins AC, Lester HA. 2004. Nicotine activation of $\alpha 4^*$ receptors: sufficient for reward, tolerance, and sensitization. *Science* **306**: 1029–1032.
- Tukey JW. 1977. *Exploratory data analysis*. Addison-Wesley, Boston.
- Upton M, Lotfipour S. 2015. $\alpha 2$ -Null mutant mice have altered levels of neuronal activity in restricted midbrain and limbic brain regions during nicotine withdrawal as demonstrated by cfos expression. *Biochem Pharmacol* **97**: 558–565.
- Wada K, Ballivet M, Boulter J, Connolly J, Wada E, Deneris ES, Swanson LW, Heinemann S, Patrick J. 1988. Functional expression of a new pharmacological subtype of brain nicotinic acetylcholine receptor. *Science* **240**: 330–334.
- Wada E, Wada K, Boulter J, Deneris E, Heinemann S, Patrick J, Swanson LW. 1989. Distribution of $\alpha 2$, $\alpha 3$, $\alpha 4$, and $\beta 2$ neuronal nicotinic receptor subunit mRNAs in the central nervous system: a hybridization histochemical study in the rat. *J Comp Neurol* **284**: 314–335.
- Wehner JM, Keller JJ, Keller AB, Picciotto MR, Paylor R, Booker TK, Beaudet A, Heinemann SF, Balogh SA. 2004. Role of neuronal nicotinic receptors in the effects of nicotine and ethanol on contextual fear conditioning. *Neuroscience* **129**: 11–24.
- Wiltgen BJ, Sanders MJ, Behne NS, Fanselow MS. 2001. Sex differences, context preexposure, and the immediate shock deficit in Pavlovian context conditioning with mice. *Behav Neurosci* **115**: 26–32.

Received February 21, 2017; accepted in revised form March 31, 2017.

α 2* Nicotinic acetylcholine receptors influence hippocampus-dependent learning and memory in adolescent mice

Shahrdad Lotfipour, Celina Mojica, Sakura Nakauchi, et al.

Learn. Mem. 2017, **24**:

Access the most recent version at doi:[10.1101/lm.045369.117](https://doi.org/10.1101/lm.045369.117)

References

This article cites 61 articles, 16 of which can be accessed free at:
<http://learnmem.cshlp.org/content/24/6/231.full.html#ref-list-1>

Creative Commons License

This article is distributed exclusively by Cold Spring Harbor Laboratory Press for the first 12 months after the full-issue publication date (see <http://learnmem.cshlp.org/site/misc/terms.xhtml>). After 12 months, it is available under a Creative Commons License (Attribution-NonCommercial 4.0 International), as described at <http://creativecommons.org/licenses/by-nc/4.0/>.

Email Alerting Service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](#).